Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 574-579

  Bakshi, Rachit ^a   Zhang, Hong ^a,b   Logan, Robert ^a   Joshi, Ila ^a   Xu, Yuehang ^a   Chen, Xiqun ^a   Schwarzschild, Michael A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Astrocytes; Glutathione; Neurons; Nrf2; Urate

Indexed keywords

GLUTATHIONE; TRANSCRIPTION FACTOR NRF2; URATE; CONDITIONED MEDIUM; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE; URIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE CULTURE; BRAIN CORTEX; CELL DEATH; CONTROLLED STUDY; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; GLUTATHIONE METABOLISM; MICROGLIA; MOUSE; NEUROLOGIC DISEASE; NEUROPROTECTION; NEWBORN; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; ACTIVE TRANSPORT; ANIMAL; CELL CULTURE; CONDITIONED MEDIUM; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY; SIGNAL TRANSDUCTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ASTROCYTES; CELLS, CULTURED; CEREBRAL CORTEX; CULTURE MEDIA, CONDITIONED; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; MICE; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; SIGNAL TRANSDUCTION; URIC ACID;

EID: 84946489184     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.08.022     Document Type: Article

References (45)

1. Ascherio A., et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 2009, 66:1460-1468.
2. Bakshi R., et al. Purines in Parkinson's: adenosine A2A receptors and urate as targets for neuroprotection. The Adenosinergic System - A Non-dopaminergic Target in PARKINSON'S Disease 2015, Springer. M. Morelli, N. Simola, J. Wardas (Eds.).
3. Behbahani H., et al. Flow cytometry as a method for studying effects of stressors on primary rat neurons. J. Neurosci. Res. 2005, 82:432-441.
4. Belanger M., Magistretti P.J. The role of astroglia in neuroprotection. Dialogues Clin. Neurosci. 2009, 11:281-295.
5. Cai J., et al. Hormonal and cell density regulation of hepatic gamma-glutamylcysteine synthetase gene expression. Mol. Pharmacol. 1995, 48:212-218.
6. Cai J., et al. Differential regulation of gamma-glutamylcysteine synthetase heavy and light subunit gene expression. Biochem. J. 1997, 326(Pt 1):167-172.
7. Chamorro A., et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014, 13:453-460.
8. Chen P.C., et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: critical role for the astrocyte. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2933-2938.
9. Chen X., et al. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:300-305.
10. Cipriani S., et al. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark. Med 2010, 4:701-712.
11. Cipriani S., et al. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. J. Neurochem. 2012, 123:172-181.
12. Cipriani S., et al. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. PLoS One 2012, 7:e37331.
13. Crawford G.D., et al. A novel N18TG2 X mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin. J. Neurosci. 1992, 12:3392-3398.
14. Drake K.R., et al. Nucleocytoplasmic distribution and dynamics of the autophagosome marker EGFP-LC3. PLoS One 2010, 5:e9806.
15. Drew R., Miners J.O. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem. Pharmacol. 1984, 33:2989-2994.
16. Dringen R., Hirrlinger J. Glutathione pathways in the brain. Biol. Chem. 2003, 384:505-516.
17. Dringen R., et al. Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J. Neurosci. 1999, 19:562-569.
18. Dringen R., Gutterer J.M., Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. Eur. J. Biochem. 2000, 267:4912-4916.
19. Du Y., et al. Astroglia-mediated effects of uric acid to protect spinal cord neurons from glutamate toxicity. Glia 2007, 55:463-472.
20. Duan W., et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J. Neurochem. 2002, 80:101-110.
21. Franklin C.C., et al. Structure, function, and post-translational regulation of the catalytic and modifier subunits of glutamate cysteine ligase. Mol. Aspects Med. 2009, 30:86-98.
22. Gong L., et al. Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3beta signaling pathway. J. Neurochem. 2012, 123:876-885.
23. Guerreiro S., et al. Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. J. Neurochem. 2009, 109:1118-1128.
24. Hirrlinger J., et al. Glutathione release from cultured brain cells: multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. J. Neurosci. Res. 2002, 69:318-326.
25. Iwata-Ichikawa E., et al. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis. J. Neurochem. 1999, 72:2334-2344.
26. Jones D.C., et al. Dopamine-induced apoptosis is mediated by oxidative stress and Is enhanced by cyanide in differentiated PC12 cells. J. Neurochem. 2000, 74:2296-2304.
27. Kensler T.W., et al. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
28. Kraft A.D., et al. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J. Neurosci. 2004, 24:1101-1112.
29. Lu S.C. Glutathione synthesis. Biochim. Biophys. Acta 2013, 1830:3143-3153.
30. Ma Q. Role of Nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 2013, 53:401-426.
31. Makar T.K., et al. Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurons: evidence that astrocytes play an important role in antioxidative processes in the brain. J. Neurochem. 1994, 62:45-53.
32. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2:679-689.
33. Moellering D., et al. Nitric oxide-dependent induction of glutathione synthesis through increased expression of gamma-glutamylcysteine synthetase. Arch. Biochem. Biophys. 1998, 358:74-82.
34. PSG, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014, 71:141-150.
35. Raps S.P., et al. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. Brain Res. 1989, 493:398-401.
36. Scannevin R.H., et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341:274-284.
37. Scott G.S., et al. Uric acid protects against secondary damage after spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3483-3488.
38. Shih A.Y., et al. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 2003, 23:3394-3406.
39. Sidoryk-Wegrzynowicz M., et al. Role of astrocytes in brain function and disease. Toxicol. Pathol. 2011, 39:115-123.
40. Todorovic M., et al. Comprehensive assessment of genetic sequence variants in the antioxidant 'master regulator' nrf2 in idiopathic Parkinson's disease. PLoS One 2015, 10:e0128030.
41. Vargas M.R., et al. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 2008, 28:13574-13581.
42. von Otter M., et al. Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson's disease - a multicenter study. BMC Med. Genet. 2014, 15:131.
43. Yu Z.F., et al. Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J. Neurosci. Res. 1998, 53:613-625.
44. Zhang N., et al. Nrf2 signaling contributes to the neuroprotective effects of urate against 6-OHDA toxicity. PLoS One 2014, 9:e100286.
45. Zhu T.G., et al. Protective effects of urate against 6-OHDA-induced cell injury in PC12 cells through antioxidant action. Neurosci. Lett. 2012, 506:175-179.